Presbia (LENSF) 10-Q 11 May 18 2018 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2018	May 11, 2018
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q1
Trading Symbol	LENS
Entity Registrant Name	PRESBIA PLC
Entity Central Index Key	1,591,096
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		17,121,857

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Current assets
Cash	$ 1,052	$ 3,236
Accounts receivable	8	8
Inventory, net	77	127
Prepaid expenses and other current assets	277	108
Total current assets	1,414	3,479
Property and equipment, net	448	477
Intangible asset	1,444	1,479
Other assets	128	127
Total assets	3,434	5,562
Current liabilities
Accounts payable	761	628
Due to related parties	32	23
Note payable, current portion	503	480
Other current liabilities	1,079	1,151
Total current liabilities	2,375	2,282
Deferred rent	103	107
Due to related parties, net of current portion		12
Other liabilities, net of current portion	28	30
Total liabilities	2,506	2,431
Commitments and contingencies (note 7)
Shareholders' equity
Ordinary Shares $0.001 par value, 350,000,000 shares authorized; 17,121,857 shares issued and outstanding at March 31, 2018 and December 31, 2017	17	17
Deferred ordinary Shares €1.00 (US$1.35) par value, 39,994 shares authorized, issued and outstanding at March 31, 2018 and December 31, 2017	54	54
Preferred Shares $0.001 par value, 50,000,000 shares authorized; -0- shares issued and outstanding at March 31, 2018 and December 31, 2017
Additional paid-in capital	91,172	91,362
Accumulated deficit	(90,315)	(88,302)
Total shareholders' equity	928	3,131
Total liabilities and shareholders’ equity	$ 3,434	$ 5,562

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical)	Mar. 31, 2018$ / sharesshares	Mar. 31, 2018€ / sharesshares	Dec. 31, 2017$ / sharesshares	Dec. 31, 2017€ / sharesshares
Statement Of Financial Position [Abstract]
Ordinary shares, par value | $ / shares	$ 0.001		$ 0.001
Ordinary shares, shares authorized	350,000,000	350,000,000	350,000,000	350,000,000
Ordinary shares, shares issued	17,121,857	17,121,857	17,121,857	17,121,857
Ordinary shares, shares outstanding	17,121,857	17,121,857	17,121,857	17,121,857
Deferred ordinary shares, par value | (per share)	$ 1.35	€ 1	$ 1.35	€ 1
Deferred ordinary shares, shares authorized	39,994	39,994	39,994	39,994
Deferred ordinary shares, shares issued	39,994	39,994	39,994	39,994
Deferred ordinary shares, shares outstanding	39,994	39,994	39,994	39,994
Preferred shares, par value | $ / shares	$ 0.001		$ 0.001
Preferred shares, shares authorized	50,000,000	50,000,000	50,000,000	50,000,000
Preferred shares, shares issued	0	0	0	0
Preferred shares, shares outstanding	0	0	0	0

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Income Statement [Abstract]
Revenues	$ 3	$ 5
Cost of goods sold	47	11
Gross loss	(44)	(6)
Operating expenses:
Research and development	709	1,842
Sales and marketing	353	961
General and administrative	861	1,754
Total operating expenses	1,923	4,557
Operating loss	(1,967)	(4,563)
Interest (expense) income	(9)	(14)
Loss before income tax provision	(1,976)	(4,577)
Income tax provision	37	16
Net loss	$ (2,013)	$ (4,593)
Net loss per ordinary share-basic and diluted	$ (0.12)	$ (0.32)
Weighted average shares outstanding - basic and diluted	17,004,755	14,265,079

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Cash flow from operating activities:
Net loss	$ (2,013)	$ (4,593)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	66	85
Inventory provisions	45	9
Stock-based compensation	(148)	523
Imputed interest expense	11	20
Changes in operating assets and liabilities:
Accounts receivable		(40)
Inventory	5	(1)
Prepaid expenses and other current assets	(169)	136
Other assets		1
Accounts payable and other current liabilities	(26)	801
Income taxes payable	86	16
Deferred rent	(4)	34
Due to related parties	(46)	4
Net cash used in operating activities	(2,193)	(3,005)
Cash flow from investing activities:
Purchases of intangible assets	(2)	(21)
Purchases of property and equipment	(2)	(8)
Net cash used in investing activities	(4)	(29)
Cash flow from financing activities:
Proceeds from issuance of ordinary shares from rights offering, net of costs		10,477
Net cash provided by financing activities		10,477
Net increase (decrease) in cash	(2,197)	7,443
Effect of exchange rate on cash	13	21
Cash balance at beginning of period	3,236	7,333
Cash balance at end of period	$ 1,052	$ 14,797

Basis of Presentation

Basis of Presentation	3 Months Ended
	Mar. 31, 2018
Accounting Policies [Abstract]
Basis of Presentation	(1) Basis of Presentation Principles of Consolidation. The accompanying consolidated financial statements have been derived from the historical cost basis of the assets and liabilities, financial condition and cash flows of Presbia PLC and Presbia Ireland, Limited, both organized in Ireland, Presbia Investments, a wholly-owned subsidiary of Presbia PLC organized in the Cayman Islands, and Presbia Ireland, Limited’s subsidiaries, Presbia Deutchland GmbH, Presbia USA, Inc., and OPL, LLC. Presbia Deutchland GmbH is organized in Germany, and Presbia USA, Inc. and OPL, LLC are both entities organized in the United States, and include Presbia USA, Inc.’s subsidiaries, Visitome, Inc. and PresbiBio, LLC, both organized in the United States, and OPL, LLC’s direct and indirect subsidiaries, PIP Holdings, C.V and Presbia Cooperatief U.A., both organized in the Netherlands, and PresbiOptical LLC, organized in the United States (collectively, including Presbia PLC, the “Company”). The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). The Company’s fiscal year ends on December 31. The entities presented in the consolidated financial statements have been under common control during the periods presented. All intercompany accounts have been eliminated in consolidation. Basis of Presentation. The accompanying unaudited consolidated financial statements as of March 31, 2018 and for the three months ended March 31, 2018 and 2017, respectively, have been prepared in accordance with United States generally accepted accounting principles (“U.S.GAAP”) for interim financial reporting, and with the instructions to Form 10-Q and Article 8 of Regulation S-X. The accompanying consolidated balance sheet at December 31, 2017 has been derived from the audited consolidated balance sheet at December 31, 2017, contained in the annual report on Form 10-K for the year ended December 31, 2017. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements presented in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2017, filed with the Securities and Exchange Commission on March 30, 2018. In the opinion of management, the accompanying consolidated financial statements reflect all adjustments which are necessary for a fair presentation of the results of operations and cash flows for the periods presented. The results of operations for such interim periods are not necessarily indicative of results of operations to be expected for the full year. References to amounts in the consolidated financial statement sections are in thousands, except per share data, unless otherwise specified. Liquidity At March 31, 2018, the Company has an accumulated deficit of $90.3 million and it expects to incur additional operating losses through 2019, and possibly further. As it continues to incur losses, the Company’s transition to profitability will depend on the successful development, approval and commercialization of its microlens. The Company may never achieve profitability, and unless and until it does, it will need to continue to raise additional capital. Based on the Company’s current business plan, management believes that its cash and cash equivalents at March 31, 2018, and the net proceeds from the April 2018 sale of $5,000,000 of preferred shares to our principle shareholder

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2018
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	(2) Summary of Significant Accounting Policies During the three months ended March 31, 2018 there have been no changes to the Company’s significant accounting policies as described in the Annual Report on Form 10-K for the fiscal year ended December 31, 2017, other than the adoption of the new revenue recognition standard noted below. Revenue Recognition Prior to 2018, we recognized revenue when there is persuasive evidence that an arrangement exists with our customers, selling prices are fixed or determinable, title or risk of loss has passed, and collection is reasonably assured. Revenue was recognized upon shipment and payments are either received in advance, or net 30 days for lenses or net 14 days for accessories. Distributor arrangements included certain perfunctory acceptance provisions and a one-year warranty, from the date of shipment, that products are free from defects in material workmanship. Under such provisions customers may reject shipments via written notifications ranging from 14-45 days or exchange defective product under warranty for the same non-defective product. We have not had any significant rejected shipments or warranty claims. We did not grant price concessions to our distributors. In 2012, we changed our commercialization strategy from exclusively using distributors to also targeting refractive laser centers equipped with femtosecond lasers, except in countries that require the use of distributors or sales representatives. In December 2017, in light our re-ordering of operational priorities, we have focused our commercialization and clinical trial efforts outside of the U.S. in Germany and South Korea, including established ophthalmic clinics in those countries. We recognize revenue from laser centers and ophthalmic clinics based upon an analysis of the terms of each customer arrangement and upon determination that persuasive evidence of an arrangement exists, selling prices are fixed or determinable, title or risk of loss has passed, and collection is reasonably assured. Revenues from laser centers and ophthalmic clinics during the periods ended March 31, 2018 and 2017 were not material. Effective January 1, 2018, the Company adopted the provisions of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (“ASC 606”), using the modified retrospective transition method. Under this method, the Company recognizes revenue based on an analysis of the goods and services provided to our customers in the ordinary course. We analyze all commercial agreements to identify (i) contracts and arrangements with customers that meet the criteria for revenue recognition under the new standard (ii) identify all performance obligations under the contractual arrangement, such as the delivery of our Microlens to our customers and any other deliverable(s) as defined in a commercial arrangement (iii) the determination of the transaction price and the allocation of such pricing over the defined contractual obligations in the contract with the customer and (iv) the recognition of revenue once the customer has assumed control over the contractual obligations. Control refers to the ability on the part of the customer to obtain substantially all the benefits of possession of the delivered product or service. If revenue transactions do not qualify as revenue under the new standard, then the previous revenue standard or other GAAP standards, as appropriate, is applied. Foreign Currency The functional currency of subsidiaries outside the United States of America is the U.S. Dollar. Transactions in foreign currencies during the year are re-measured at rates of exchange on the dates of the transactions. Gains and losses related to re-measurement of items arising through operating activities are accounted for in the statement of operations and comprehensive loss and included in general and administrative expense. Aggregate foreign exchange loss is included in the Condensed Consolidated Statement of Operations and it was $52,000 and $27,000 for the periods ended March 31, 2018 and 2017, respectively. Comprehensive Loss Comprehensive income or loss is defined as a change in equity of a company attributable to all transactions excluding those transactions resulting from investment with owners and distributions to owners. There were no differences between net loss and comprehensive loss in the periods ended March 31, 2018 and 2017 . Future Accounting Pronouncements In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). The new standard requires lessees to recognize most leases on their balance sheets as lease liabilities with corresponding right-of-use assets and eliminates certain real estate-specific provisions. ASU 2016-02 will be effective for the Company in the first quarter of 2019. ASU 2016-02 will be adopted on a modified retrospective transition basis for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. Although the Company is currently evaluating the full impact of ASU 2016-02 on its consolidated financial statements, upon adoption of ASU 2016-2 the Company anticipates that its operating leases will be recognized on the balance sheet as a lease liability if certain criteria is met, with a corresponding right of use asset. In February 2018, the FASB issued ASU 2018-02, Income Statement—Reporting Comprehensive Income (Topic 220)—Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. This update was issued to address the income tax accounting treatment of the stranded tax effects within other comprehensive income due to the prohibition of backward tracing due to an income tax rate change that was initially recorded in other comprehensive income. This issue came about from the enactment of the Tax Cuts and Jobs Act on December 22, 2017, which changed the Company’s income tax rate from 35% to 21%. The ASU changed current accounting whereby an entity may elect to reclassify the stranded tax effect from accumulated other comprehensive income to retained earnings. The ASU is effective for periods beginning after December 15, 2018, although early adoption is permitted. The Company does not anticipate that the adoption of this ASU will have a material impact on its consolidated financial statements. Recent Accounting Standards In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606). The new standard is based on the principle that revenue should be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 became effective for the Company in the first quarter of 2018 and allowed for full retrospective or a modified retrospective adoption approach. The Company adopted this new standard in January 2018 and it did not have a material adjustment on the basis of either a full retrospective or the modified retrospective restatements of 2016 and 2017. In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows In October 2016, the FASB issued ASU. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other than Inventory. In May 2017, the FASB issued ASU 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting,

Loss per Share

Loss per Share	3 Months Ended
	Mar. 31, 2018
Earnings Per Share [Abstract]
Loss per Share	(3) Loss per Share Basic net loss per ordinary share is calculated by dividing net loss allocated to ordinary shareholders by the weighted average number of ordinary shares outstanding during the reporting period, excluding unvested restricted stock awards. Diluted net loss allocated to ordinary shareholders per share is calculated based on the weighted average number of Ordinary Shares and dilutive potential Ordinary Shares outstanding during the period. Dilutive potential ordinary shares consist of the shares issuable upon the exercise of options and upon the vesting of restricted shares under the treasury stock method. In net loss periods, basic and diluted net loss per share are identical since the effect of potential ordinary shares is anti-dilutive and therefore excluded. Basic and diluted loss per share for the three months ended March 31, 2018 and 2017 were calculated as follows: Three-Months Ended March 31, 2018 2017 Net Loss $ (2,013 ) $ (4,593 ) Weighted average shares outstanding - basic and diluted 17,004,755 14,265,079 Net loss per ordinary share - basic and diluted $ (0.12 ) $ (0.32 ) Antidilutive securities, which consist of options and unvested restricted shares that are not included in the diluted net loss per share calculation, consisted of an aggregate of approximately 840,033 and 1,050,000 weighted average shares for the three months ended March 31, 2018 and 2017, respectively.

Equity Based Awards

Equity Based Awards	3 Months Ended
	Mar. 31, 2018
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Equity Based Awards	(4) Equity Based Awards Equity Issued by Presbia PLC Presbia Incentive Plan On January 14, 2015, the Company approved a compensation incentive plan (the “Presbia Incentive Plan”). The Presbia Incentive Plan permits the Company to grant awards of options, restricted shares, share appreciation rights, restricted share units, performance shares, performance share units, dividend equivalent rights in respect of awards and other share-based and cash-based awards, including annual and long-term cash incentive awards. A total of 2,200,000 ordinary shares are authorized for issuance under the Presbia Incentive Plan of which approximately 605,891 were available on March 31, 2018 for future grants and awards. The exercise price of each option award shall be determined by the Board of Directors (or a committee thereof) at the date of grant in accordance with the terms of the 2005 Plan, and under the Presbia Incentive Plan awards generally vest 20% annually over a five-year period and expire no later than 10 years from the grant date. The Presbia Incentive Plan terminates on January 14, 2025, unless terminated earlier by the board of directors. Awards under the Presbia Incentive Plan may be granted to employees, directors, consultants and other persons who perform services for the Company or a subsidiary of the Company. The following table shows share-based compensation expense based upon all equity awards issued by Presbia PLC included in the Consolidated Statements of Operations for the three months ended March 31, 2018 and 2017. The Company recorded a credit of $438,000 as a result of the unwinding of stock-based compensation for participants who exited the Company in the first quarter of 2018. Three-Months Ended March 31, 2018 2017 Research and development $ (177 ) $ 116 General and administrative $ (1 ) 331 Sales and marketing $ 30 76 $ (148 ) $ 523 Options The following table sets forth the Company’s option activity for the three months ended March 31, 2018: Number of Presbia PLC Shares Weighted Average Exercise Price Per Share Balance, January 1, 2018 849,100 $ 9.77 Granted — — Exercised — — Forfeited/cancelled/expired (15,750 ) $ 8.60 Balance, March 31, 2018 833,350 $ 9.80 Vested, March 31, 2018 725,400 $ 9.83 Non Vested, March 31, 2018 107,950 $ 9.59 Exercisable, March 31, 2018 725,400 $ 9.83 Employee Options The Company utilizes the Black-Scholes valuation model for estimating the fair value of granted stock options with the following assumptions in addition to the closing price of the Company’s ordinary shares on the date of the grant: (i) the Company estimates the expected term of the option utilizing the simplified method because of its limited history of option exercise activity and its options meet the criteria of a "plain-vanilla" option as defined by the Securities Exchange Commission (ii) due to its limited stock price volatility history, the Company uses a peer group average as permitted under Accounting Standards Codification (“ASC”) 718 consistent with the expected term of the stock option at the time of the grant and (iii) applies a risk-free interest rate based on the U.S. Treasury securities yield consistent with the expected term of the option at the time of the grant. The simplified method calculates the expected term as the average of the weighted average vesting period and contractual terms of the award. For those options granted to employees, stock-based compensation expense was based upon the fair value of the option as of the grant-date and attributed to future reporting periods on a straight-line basis over the vesting period, or the requisite service period. The Company adopted ASU 2016-09 on January 01, 2018, electing to account for forfeitures when they occur. The Company did not issue employee options during the three months ended March 31, 2018 and 2017. Non-Employee Options During the three months ended March 31, 2018 and 2017, the Company did not grant options to non-employee consultants and medical advisors. In contrast to the determination of the fair value of options granted to employees, which are determined based upon the grant-date assumptions and applying the Black-Scholes model, the fair values for non-employee options and the related stock-based compensation expense are remeasured each financial reporting period based upon the assumptions applicable on the dates in which the financial statements are prepared, which are disclosed in the following table: Three-Months Ended March 31, 2018 Three-Months Ended March 31, 2017 Stock price per share $1.23 - $1.43 $2.08 - $2.51 Expected term 6.84 - 7.4 Yrs. 7.96 - 8.6 Yrs. Volatility 76.5% - 77.3% 82.8% - 90.0% Dividends — — Risk-free rate 2.7% 2.3% Because the performance criteria of these grants is based solely upon a requisite service period, but are subject to forfeiture if the service conditions are not met, stock-based compensation expense is determined by a straight-line attribution of the remeasured expense (mark-to-market) over the requisite service period subject to forfeitures when they occur. Restricted Shares The Company’s board of directors did not grant restricted ordinary shares of the Company during the three month period ended March 31, 2018. The following table sets forth the Company’s restricted share activity for the three months ended March 31, 2018: Unvested Number of Shares Weighted Average Fair Value per Share Balance, December 31, 2017 134,367 $ 3.78 Granted — $ — Vested (81,476 ) $ 3.26 Forfeited/cancelled — Unvested, March 31, 2018 52,891 $ 5.45 Restricted Share Units During the three months ended March 31, 2018 and 2017, the Board of Directors approved the award of 0 and 55,000 restricted share units (“RSU” or “RSU’s” or “RSU Plan”), respectively, to officers and employees in accordance with the guidelines provided by the Presbia Incentive Plan, which includes a provision that the recipient must be employed as a condition of vesting. The Presbia RSU Plan authorizes the issuance of 20% of each recipient’s total RSU award for the first occurrence that the closing price of the Company’s ordinary shares exceed, for a period of 20 consecutive business days, price thresholds of $10.00, $15.00, $20.00, $25.00 and $30.00, respectively. The RSU Plan also provides for a one-year “wait” or service period prior to any vesting permitted under the plan. The RSU Plan has a seven-year expiration period following the date of the grant. Fair value of the RSU’s awarded were determined using a Monte Carlo Simulation (“MCS”) methodology, which considers the separate probabilities that each of the price thresholds or market conditions will be achieved under the RSU Plan guidelines. Each probability is weighted by its respective price threshold, or its intrinsic value, which provides the basis for an aggregate fair value. The Company used the following key inputs in determining the fair value using the MCS model: (i) the volatility of the entity’s common stock and (ii) the closing price of the entity’s stock as of the measurement date of the RSU award. In accordance with GAAP, the Company recognizes as stock-based compensation expense, using a straight-line attribution method, the aggregate fair value over future periods based upon the respective derived service periods and fair values for each of the price thresholds as provided by the MCS model. The following table sets forth the Company’s RSU activity for the three months ended March 31, 2018: Unvested Number of Shares Weighted Average Fair Value per Share Balance, December 31, 2017 739,000 $ 2.09 Granted — $ — Vested — — Forfeited/cancelled (155,000 ) 2.67 Unvested, March 31, 2018 584,000 $ 1.17 Unrecognized Share-based Compensation As of March 31, 2018 and 2017, there were $379,000 and $3,026,000, respectively, of unrecognized compensation expense related to employee and non-employee options of the Company, which collectively is expected to be recognized by the Company over the weighted average vesting period of 1.4 and 1.9 years, respectively. Unrecognized compensation expense for the same periods related to restricted shares was $248,000 and $480,000, respectively, and is expected to be recognized over the weighted average vesting periods of 1.9 and 1.6 years, respectively. As of March 31, 2018 and 2017, there was approximately $1,030,000 and 1,682,000 of unrecognized compensation expense with respect to the RSU’s over a weighted average remaining derived service period of 1.4 and 2.1 years, respectively.

Concentration of Credit Risk

Concentration of Credit Risk	3 Months Ended
	Mar. 31, 2018
Risks And Uncertainties [Abstract]
Concentration of Credit Risk	(5) Concentration of Credit Risk The Company had cash of $1.1 million and $3.2 million as of March 31, 2018 and December 31, 2017, respectively, which consists of checking account deposits. The Company maintains cash balances at financial institutions located in the United States and secured by the Federal Deposit Insurance Corporation up to $250,000. As of March 31, 2018, the Company was not authorized to manufacture or sell any of its products or services within the United States and, as a result, all of the Company’ revenues are derived from foreign customers. With respect to suppliers for the microlens, the Company had a five-year supplier agreement that expired in January 2017 with a lens manufacturer in Israel from which the Company received 100% of its lens supply for use in commercial activities outside the United States. The Company also has its own manufacturing facility in Irvine, California that we believe can be scaled to meet excessive lens demand or a disruption of supply sourced from outside the United States.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2018
Income Tax Disclosure [Abstract]
Income Taxes	(6) Income Taxes Deferred income tax assets and liabilities are recognized for temporary differences between financial statement and income tax carrying values, using tax rates in effect for the years such differences are expected to reverse. Due to uncertainties surrounding the Company's ability to generate future taxable income and consequently realize such deferred income tax assets, a full valuation allowance has been established. The Company continues to maintain a full valuation allowance against its deferred tax assets as of March 31, 2018. The impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more likely than not to be sustained upon audit by the relevant tax authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. In December 2017, the Company recorded a liability of $199,000 with respect to unpaid Irish income taxes in accordance with FIN 48, Accounting for Uncertainty of Income Taxes, and increased that liability during the three months ended March 31, 2018 to $290,000. The Company’s policy is to recognize interest expense and penalties related to income tax matters as a component of the income tax provision. As of March 31, 2018 and December 31, 2017, the Company had $37,000 and $39,000, respectively, of tax related accrued interest and penalties on its consolidated balance sheet or on its consolidated statement of operations. A reconciliation of gross unrecognized tax benefits is as follows: March 31, 2018 December 31, 2017 Balance at the beginning of the year 199,000 — Increases related to current year tax positions 91,000 199,000 Balance at the end of the year $ 290,000 $ 199,000

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2018
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	(7) Commitments and Contingencies In May 2012, the Company entered into a five-year non-cancelable lease for office and manufacturing space in Irvine, California that was renewed on June 1, 2016 and provided for an extension of five consecutive years starting from the original lease expiration date of May 31, 2017 through May 31, 2022. The Company maintains a one-year lease (which is now month to month) in Dublin, Ireland that commenced on December 1, 2013. In February 2018, it terminated a 30-month lease in Amsterdam, the Netherlands, that commenced on January 1, 2016. This termination was based on a mutual agreement with the landlord. In December 2017, the Company vacated one of its Irvine, California locations and consolidated its operations into another location in Irvine. At March 31, 2018 and December 31, 2017, liabilities of $156,000 and $222,000, respectively, representing the fair value of the remaining lease obligation over the remaining 30 and 33 months, respectively, were recorded as part of the short-term portion of deferred rent in the Consolidated Balance Sheet. These liabilities include the effects of assumptions related to prospective sublease arrangements, which are subject to the Company’s best judgement regarding the likelihood of occurrence and the timing of any amounts resulting from a sublease agreement. Aggregate rent expense for the three months ended March 31, 2018 and 2017 was $95,000 and $169,000, respectively. From time to time, the Company may be subject to legal proceedings and claims arising in the ordinary course of business. Management does not believe that the outcome of any of these matters will have a material effect on the Company’s consolidated financial operations .

Subsequent Event

Subsequent Event	3 Months Ended
	Mar. 31, 2018
Subsequent Events [Abstract]
Subsequent Event	(8) Subsequent Event On April 12, 2018, the Company and its wholly-owned subsidiary, Presbia USA, Inc. (the “Subsidiary”) and Richard Ressler, a member of the Company’s board of directors and its majority stockholder, entered into a Stock Purchase Agreement pursuant to which Mr. Ressler purchased in a private placement (the “Offering”) 100 preferred shares of the Company, with the rights set forth in the Subscription Letter, dated April 12, 2018, (the “Preferred Shares”) and 4,900 shares of preferred stock of the Subsidiary (the “Subsidiary Preferred Shares”) for an aggregate purchase price of $5,000,000. Upon closing the Offering, Mr. Ressler received a warrant (the “Warrants”) to purchase 1,953,125 ordinary shares of the Company at an exercise price of $2.56 per share, subject to adjustments as provided under the terms of the Warrants. The Warrant is exercisable for five years from the issuance date. The Warrant contains cashless exercise provisions. The Preferred Shares and the Subsidiary Preferred Shares carry a one time liquidation preference. The Preferred Shares and Subsidiary Preferred Shares are redeemable upon a liquidation event in which all classes of equity holders are entitled to receive the same form of consideration and are redeemable at any time at the Company’s sole election, provided that a majority of the independent directors approve such redemption. The preferred shares accrue a dividend at the rate of 10% per annum during the first 18 months, 20% for months 19 through 24 and 30% from month 25 until such preferred shares are redeemed, payable in preferred shares on a quarterly basis. As long as the Preferred Shares or Subsidiary Preferred Shares remain outstanding, neither the Company nor the Subsidiary shall take the following actions, without obtaining the prior consent of the holder of the Preferred Shares: (a) effect any alteration, repeal, change or amendment of the rights, privileges or preferences of the Preferred Shares or the Subsidiary Preferred Shares in a manner that adversely affects the rights, privileges or preferences of those shares or any series thereof; (b) amend, modify or repeal any provision of the organizational documents in a manner that adversely affects the powers, preferences or rights of the Preferred Shares or Subsidiary Preferred Shares; (c) agree to any debt financing in an amount in excess of $8,000,000 (such amount being the maximum amount payable by the company under the debt instruments); (d) execute a guarantee; (e) effect any restructuring or liquidation; (f) settle any lawsuit or civil investigation requiring the payment of more than $1,000,000; or (g) execute any document or enter into any arrangement that has a potential liability to the Company in excess of $1,000,000. In addition, the Company guaranteed the Subsidiary’s payment of the redemption price and any accrued and unpaid dividends with respect to the Subsidiary Preferred Shares.

Basis of Presentation (Policies

Basis of Presentation (Policies)	3 Months Ended
	Mar. 31, 2018
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation. The accompanying consolidated financial statements have been derived from the historical cost basis of the assets and liabilities, financial condition and cash flows of Presbia PLC and Presbia Ireland, Limited, both organized in Ireland, Presbia Investments, a wholly-owned subsidiary of Presbia PLC organized in the Cayman Islands, and Presbia Ireland, Limited’s subsidiaries, Presbia Deutchland GmbH, Presbia USA, Inc., and OPL, LLC. Presbia Deutchland GmbH is organized in Germany, and Presbia USA, Inc. and OPL, LLC are both entities organized in the United States, and include Presbia USA, Inc.’s subsidiaries, Visitome, Inc. and PresbiBio, LLC, both organized in the United States, and OPL, LLC’s direct and indirect subsidiaries, PIP Holdings, C.V and Presbia Cooperatief U.A., both organized in the Netherlands, and PresbiOptical LLC, organized in the United States (collectively, including Presbia PLC, the “Company”). The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). The Company’s fiscal year ends on December 31. The entities presented in the consolidated financial statements have been under common control during the periods presented. All intercompany accounts have been eliminated in consolidation.
Basis of Presentation	Basis of Presentation. The accompanying unaudited consolidated financial statements as of March 31, 2018 and for the three months ended March 31, 2018 and 2017, respectively, have been prepared in accordance with United States generally accepted accounting principles (“U.S.GAAP”) for interim financial reporting, and with the instructions to Form 10-Q and Article 8 of Regulation S-X. The accompanying consolidated balance sheet at December 31, 2017 has been derived from the audited consolidated balance sheet at December 31, 2017, contained in the annual report on Form 10-K for the year ended December 31, 2017. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements presented in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2017, filed with the Securities and Exchange Commission on March 30, 2018. In the opinion of management, the accompanying consolidated financial statements reflect all adjustments which are necessary for a fair presentation of the results of operations and cash flows for the periods presented. The results of operations for such interim periods are not necessarily indicative of results of operations to be expected for the full year. References to amounts in the consolidated financial statement sections are in thousands, except per share data, unless otherwise specified.
Liquidity	Liquidity At March 31, 2018, the Company has an accumulated deficit of $90.3 million and it expects to incur additional operating losses through 2019, and possibly further. As it continues to incur losses, the Company’s transition to profitability will depend on the successful development, approval and commercialization of its microlens. The Company may never achieve profitability, and unless and until it does, it will need to continue to raise additional capital. Based on the Company’s current business plan, management believes that its cash and cash equivalents at March 31, 2018, and the net proceeds from the April 2018 sale of $5,000,000 of preferred shares to our principle shareholder
Revenue Recognition	Revenue Recognition Prior to 2018, we recognized revenue when there is persuasive evidence that an arrangement exists with our customers, selling prices are fixed or determinable, title or risk of loss has passed, and collection is reasonably assured. Revenue was recognized upon shipment and payments are either received in advance, or net 30 days for lenses or net 14 days for accessories. Distributor arrangements included certain perfunctory acceptance provisions and a one-year warranty, from the date of shipment, that products are free from defects in material workmanship. Under such provisions customers may reject shipments via written notifications ranging from 14-45 days or exchange defective product under warranty for the same non-defective product. We have not had any significant rejected shipments or warranty claims. We did not grant price concessions to our distributors. In 2012, we changed our commercialization strategy from exclusively using distributors to also targeting refractive laser centers equipped with femtosecond lasers, except in countries that require the use of distributors or sales representatives. In December 2017, in light our re-ordering of operational priorities, we have focused our commercialization and clinical trial efforts outside of the U.S. in Germany and South Korea, including established ophthalmic clinics in those countries. We recognize revenue from laser centers and ophthalmic clinics based upon an analysis of the terms of each customer arrangement and upon determination that persuasive evidence of an arrangement exists, selling prices are fixed or determinable, title or risk of loss has passed, and collection is reasonably assured. Revenues from laser centers and ophthalmic clinics during the periods ended March 31, 2018 and 2017 were not material. Effective January 1, 2018, the Company adopted the provisions of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (“ASC 606”), using the modified retrospective transition method. Under this method, the Company recognizes revenue based on an analysis of the goods and services provided to our customers in the ordinary course. We analyze all commercial agreements to identify (i) contracts and arrangements with customers that meet the criteria for revenue recognition under the new standard (ii) identify all performance obligations under the contractual arrangement, such as the delivery of our Microlens to our customers and any other deliverable(s) as defined in a commercial arrangement (iii) the determination of the transaction price and the allocation of such pricing over the defined contractual obligations in the contract with the customer and (iv) the recognition of revenue once the customer has assumed control over the contractual obligations. Control refers to the ability on the part of the customer to obtain substantially all the benefits of possession of the delivered product or service. If revenue transactions do not qualify as revenue under the new standard, then the previous revenue standard or other GAAP standards, as appropriate, is applied.
Foreign Currency	Foreign Currency The functional currency of subsidiaries outside the United States of America is the U.S. Dollar. Transactions in foreign currencies during the year are re-measured at rates of exchange on the dates of the transactions. Gains and losses related to re-measurement of items arising through operating activities are accounted for in the statement of operations and comprehensive loss and included in general and administrative expense. Aggregate foreign exchange loss is included in the Condensed Consolidated Statement of Operations and it was $52,000 and $27,000 for the periods ended March 31, 2018 and 2017, respectively.
Comprehensive Loss	Comprehensive Loss Comprehensive income or loss is defined as a change in equity of a company attributable to all transactions excluding those transactions resulting from investment with owners and distributions to owners. There were no differences between net loss and comprehensive loss in the periods ended March 31, 2018 and 2017 .
Future Accounting Pronouncements	Future Accounting Pronouncements In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). The new standard requires lessees to recognize most leases on their balance sheets as lease liabilities with corresponding right-of-use assets and eliminates certain real estate-specific provisions. ASU 2016-02 will be effective for the Company in the first quarter of 2019. ASU 2016-02 will be adopted on a modified retrospective transition basis for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. Although the Company is currently evaluating the full impact of ASU 2016-02 on its consolidated financial statements, upon adoption of ASU 2016-2 the Company anticipates that its operating leases will be recognized on the balance sheet as a lease liability if certain criteria is met, with a corresponding right of use asset. In February 2018, the FASB issued ASU 2018-02, Income Statement—Reporting Comprehensive Income (Topic 220)—Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income. This update was issued to address the income tax accounting treatment of the stranded tax effects within other comprehensive income due to the prohibition of backward tracing due to an income tax rate change that was initially recorded in other comprehensive income. This issue came about from the enactment of the Tax Cuts and Jobs Act on December 22, 2017, which changed the Company’s income tax rate from 35% to 21%. The ASU changed current accounting whereby an entity may elect to reclassify the stranded tax effect from accumulated other comprehensive income to retained earnings. The ASU is effective for periods beginning after December 15, 2018, although early adoption is permitted. The Company does not anticipate that the adoption of this ASU will have a material impact on its consolidated financial statements.
Recent Accounting Standards	Recent Accounting Standards In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606). The new standard is based on the principle that revenue should be recognized to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2014-09 became effective for the Company in the first quarter of 2018 and allowed for full retrospective or a modified retrospective adoption approach. The Company adopted this new standard in January 2018 and it did not have a material adjustment on the basis of either a full retrospective or the modified retrospective restatements of 2016 and 2017. In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows In October 2016, the FASB issued ASU. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other than Inventory. In May 2017, the FASB issued ASU 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting,

Loss per Share (Tables)

Loss per Share (Tables)	3 Months Ended
	Mar. 31, 2018
Earnings Per Share [Abstract]
Schedule of Calculation of Basic and Diluted Loss per Share	Basic and diluted loss per share for the three months ended March 31, 2018 and 2017 were calculated as follows: Three-Months Ended March 31, 2018 2017 Net Loss $ (2,013 ) $ (4,593 ) Weighted average shares outstanding - basic and diluted 17,004,755 14,265,079 Net loss per ordinary share - basic and diluted $ (0.12 ) $ (0.32 )

Equity Based Awards (Tables)

Equity Based Awards (Tables)	3 Months Ended
	Mar. 31, 2018
Share-Based Compensation Expense Included in Consolidated Statements of Operations	The following table shows share-based compensation expense based upon all equity awards issued by Presbia PLC included in the Consolidated Statements of Operations for the three months ended March 31, 2018 and 2017. The Company recorded a credit of $438,000 as a result of the unwinding of stock-based compensation for participants who exited the Company in the first quarter of 2018. Three-Months Ended March 31, 2018 2017 Research and development $ (177 ) $ 116 General and administrative $ (1 ) 331 Sales and marketing $ 30 76 $ (148 ) $ 523
Schedule of Option Activity	The following table sets forth the Company’s option activity for the three months ended March 31, 2018: Number of Presbia PLC Shares Weighted Average Exercise Price Per Share Balance, January 1, 2018 849,100 $ 9.77 Granted — — Exercised — — Forfeited/cancelled/expired (15,750 ) $ 8.60 Balance, March 31, 2018 833,350 $ 9.80 Vested, March 31, 2018 725,400 $ 9.83 Non Vested, March 31, 2018 107,950 $ 9.59 Exercisable, March 31, 2018 725,400 $ 9.83
Schedule of Restricted Shares Activity	The following table sets forth the Company’s restricted share activity for the three months ended March 31, 2018: Unvested Number of Shares Weighted Average Fair Value per Share Balance, December 31, 2017 134,367 $ 3.78 Granted — $ — Vested (81,476 ) $ 3.26 Forfeited/cancelled — Unvested, March 31, 2018 52,891 $ 5.45
Schedule of RSU Activity	The following table sets forth the Company’s RSU activity for the three months ended March 31, 2018: Unvested Number of Shares Weighted Average Fair Value per Share Balance, December 31, 2017 739,000 $ 2.09 Granted — $ — Vested — — Forfeited/cancelled (155,000 ) 2.67 Unvested, March 31, 2018 584,000 $ 1.17
Non-employee options [Member]
Schedule of Black-Scholes Valuation Model Assumptions for Estimating the Fair Value of Share-Based Compensation	During the three months ended March 31, 2018 and 2017, the Company did not grant options to non-employee consultants and medical advisors. In contrast to the determination of the fair value of options granted to employees, which are determined based upon the grant-date assumptions and applying the Black-Scholes model, the fair values for non-employee options and the related stock-based compensation expense are remeasured each financial reporting period based upon the assumptions applicable on the dates in which the financial statements are prepared, which are disclosed in the following table: Three-Months Ended March 31, 2018 Three-Months Ended March 31, 2017 Stock price per share $1.23 - $1.43 $2.08 - $2.51 Expected term 6.84 - 7.4 Yrs. 7.96 - 8.6 Yrs. Volatility 76.5% - 77.3% 82.8% - 90.0% Dividends — — Risk-free rate 2.7% 2.3%

Income Taxes (Tables)

Income Taxes (Tables)	3 Months Ended
	Mar. 31, 2018
Income Tax Disclosure [Abstract]
Schedule of Reconciliation of Gross Unrecognized Tax Benefits	A reconciliation of gross unrecognized tax benefits is as follows: March 31, 2018 December 31, 2017 Balance at the beginning of the year 199,000 — Increases related to current year tax positions 91,000 199,000 Balance at the end of the year $ 290,000 $ 199,000

Basis of Presentation - Additio

Basis of Presentation - Additional Information (Detail) - USD ($)	Apr. 12, 2018	Mar. 31, 2018	Dec. 31, 2017
Basis Of Presentation [Line Items]
Accumulated deficit		$ 90,315,000	$ 88,302,000
Subsequent Event [Member] | Richard Ressler [Member] | Preferred Shares [Member] | Private Placement [Member]
Basis Of Presentation [Line Items]
Net proceeds from sale of preferred shares	$ 5,000,000

Summary of Significant Accoun19

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
Subsidiary Sale Of Stock [Line Items]
Warranty period, from the date of shipment	1 year
Income tax rate	21.00%		35.00%
General and Administrative Expense [Member]
Subsidiary Sale Of Stock [Line Items]
Aggregate foreign exchange loss	$ 52,000	$ 27,000
Minimum [Member]
Subsidiary Sale Of Stock [Line Items]
Written notification period to reject shipments by customers	14 days
Maximum [Member]
Subsidiary Sale Of Stock [Line Items]
Written notification period to reject shipments by customers	45 days
Lenses [Member]
Subsidiary Sale Of Stock [Line Items]
Payments collection period	30 days
Accessories [Member]
Subsidiary Sale Of Stock [Line Items]
Payments collection period	14 days

Loss per Share - Schedule of Ca

Loss per Share - Schedule of Calculation of Basic and Diluted Loss per Share (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Basic and diluted net loss per share
Net Loss	$ (2,013)	$ (4,593)
Weighted average shares outstanding - basic and diluted	17,004,755	14,265,079
Net loss per ordinary share - basic and diluted	$ (0.12)	$ (0.32)

Loss per Share - Additional Inf

Loss per Share - Additional Information (Detail) - shares	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Earnings Per Share [Abstract]
Antidilutive securities, not included in diluted net loss per calculation	840,033	1,050,000

Equity Based Awards - Additiona

Equity Based Awards - Additional Information (Detail) - USD ($)	Jan. 14, 2015	Mar. 31, 2018	Mar. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Unwinding of stock-based compensation for exited participants		$ 438,000
Non-employee consultants and medical advisors [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Options granted		0	0
Employee options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Options granted		0	0
Restricted shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Restricted shares granted		0
Unrecognized compensation expense, weighted average period of recognition		1 year 10 months 24 days	1 year 7 months 6 days
Unrecognized compensation expense related to restricted shares/RSUs		$ 248,000	$ 480,000
Restricted Share Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Award expiration period		7 years
Restricted shares granted		0	55,000
Authorized issuance percentage of each recipient’s total RSU award		20.00%
Consecutive trading days		20 days
Wait or service period		1 year
Unrecognized compensation expense, weighted average period of recognition		1 year 4 months 24 days	2 years 1 month 6 days
Unrecognized compensation expense related to restricted shares/RSUs		$ 1,030,000	$ 1,682,000
Employee and non-employee options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Unrecognized compensation expense related to options		$ 379,000	$ 3,026,000
Unrecognized compensation expense, weighted average period of recognition		1 year 4 months 24 days	1 year 10 months 24 days
Threshold Price Period 1 [Member] | Restricted Share Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share price threshold		$ 10
Threshold Price Period 2 [Member] | Restricted Share Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share price threshold		15
Threshold Price Period 3 [Member] | Restricted Share Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share price threshold		20
Threshold Price Period 4 [Member] | Restricted Share Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share price threshold		25
Threshold Price Period 5 [Member] | Restricted Share Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Share price threshold		$ 30
Presbia Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Awards vesting period	5 years
Ordinary shares authorized for issuance	2,200,000
Ordinary shares available for future grants and awards		605,891
Award expiration period	10 years
Award expiration date		Jan. 14, 2025
Presbia Incentive Plan [Member] | Over five year period [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Generally vesting percentage for annual	20.00%

Equity Based Awards - Share-Bas

Equity Based Awards - Share-Based Compensation Expense Included in Consolidated Statements of Operations (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	$ (148)	$ 523
Research and development [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	(177)	116
General and administrative [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	(1)	331
Sales and marketing [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Share-based compensation expense	$ 30	$ 76

Equity Based Awards - Schedule

Equity Based Awards - Schedule of Option Activity (Detail)	3 Months Ended
	Mar. 31, 2018$ / sharesshares
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Number of Presbia PLC Shares, Beginning Balance | shares	849,100
Number of Presbia PLC Shares, Forfeited/cancelled/expired | shares	(15,750)
Number of Presbia PLC Shares, Ending Balance | shares	833,350
Number of Presbia PLC Shares, Vested | shares	725,400
Number of Presbia PLC Shares, Non Vested | shares	107,950
Number of Presbia PLC Shares, Exercisable | shares	725,400
Weighted Average Exercise Price Per Share, Beginning Balance | $ / shares	$ 9.77
Weighted Average Exercise Price Per Share, Forfeited/cancelled/expired | $ / shares	8.60
Weighted Average Exercise Price Per Share, Ending Balance | $ / shares	9.80
Weighted Average Exercise Price Per Share, Vested | $ / shares	9.83
Weighted Average Exercise Price Per Share, Non Vested | $ / shares	9.59
Weighted Average Exercise Price Per Share, Exercisable | $ / shares	$ 9.83

Equity Based Awards - Schedul25

Equity Based Awards - Schedule of Black-Scholes Valuation Model Assumptions for Estimating the Fair Value of Share-Based Compensation (Detail) - Non-employee options [Member] - $ / shares	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Volatility minimum	76.50%	82.80%
Volatility maximum	77.30%	90.00%
Risk-free rate	2.70%	2.30%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock price per share	$ 1.23	$ 2.08
Expected term	6 years 10 months 2 days	7 years 11 months 15 days
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Stock price per share	$ 1.43	$ 2.51
Expected term	7 years 4 months 24 days	8 years 7 months 6 days

Equity Based Awards - Schedul26

Equity Based Awards - Schedule of Restricted Share Activity (Detail) - Restricted shares [Member]	3 Months Ended
	Mar. 31, 2018$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Unvested Number of Shares, Beginning Balance	134,367
Unvested Number of Shares, Granted	0
Unvested Number of Shares, Vested	(81,476)
Unvested Number of Shares, Ending Balance	52,891
Weighted Average Fair Value per Share, Beginning Balance | $ / shares	$ 3.78
Weighted Average Fair Value per Share, Vested | $ / shares	3.26
Weighted Average Fair Value per Share, Ending Balance | $ / shares	$ 5.45

Equity Based Awards - Schedul27

Equity Based Awards - Schedule of RSU Activity (Detail) - Restricted Share Units [Member] - $ / shares	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Unvested Number of Shares, Beginning Balance	739,000
Unvested Number of Shares, Granted	0	55,000
Unvested Number of Shares, Forfeited/cancelled	(155,000)
Unvested Number of Shares, Ending Balance	584,000
Weighted Average Fair Value per Share, Beginning Balance	$ 2.09
Weighted Average Fair Value per Share, Forfeited/cancelled	2.67
Weighted Average Fair Value per Share, Ending Balance	$ 1.17

Concentration of Credit Risk -

Concentration of Credit Risk - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2018	Dec. 31, 2017	Mar. 31, 2017	Dec. 31, 2016
Concentration Risk [Line Items]
Cash	$ 1,052,000	$ 3,236,000	$ 14,797,000	$ 7,333,000
Supplier agreement term	5 years
Supplier agreement, expiration date	2017-01
Cost of Goods, Total [Member] | Supplier Concentration Risk [Member]
Concentration Risk [Line Items]
Concentration risk percentage	100.00%
Federal Deposit Insurance Corporation [Member] | Maximum [Member]
Concentration Risk [Line Items]
Cash	$ 250,000

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Income Tax [Line Items]
Description of uncertain income tax position being recognized	An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained.
Liability for unpaid irish income taxes	$ 290,000	$ 199,000	$ 0
Accrued interest and penalties	37,000	39,000
Foreign [Member] | Ireland [Member]
Income Tax [Line Items]
Liability for unpaid irish income taxes	$ 290,000	$ 199,000

Income Taxes - Schedule of Reco

Income Taxes - Schedule of Reconciliation of Gross Unrecognized Tax Benefits (Detail) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2018	Dec. 31, 2017
Income Tax Disclosure [Abstract]
Balance at the beginning of the year	$ 199,000	$ 0
Increases related to current year tax positions	91,000	199,000
Balance at the end of the year	$ 290,000	$ 199,000

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail)	Jun. 01, 2016	Jan. 02, 2016	Dec. 01, 2013	May 31, 2012	Dec. 31, 2017USD ($)Facility	Mar. 31, 2018USD ($)	Mar. 31, 2017USD ($)	Dec. 31, 2017USD ($)
Commitments And Contingencies [Line Items]
Rent expense						$ 95,000	$ 169,000
California [Member]
Commitments And Contingencies [Line Items]
Lease period				5 years
Lease expiration period	May 31, 2022			May 31, 2017
Lease renewal term	5 years
Ireland [Member]
Commitments And Contingencies [Line Items]
Lease period			1 year
Lease renewal term			1 month
Lease commencement date			Dec. 1, 2013
The Netherlands [Member]
Commitments And Contingencies [Line Items]
Lease period		30 months
Lease commencement date		Jan. 1, 2016
Lease termination period		2018-02
Reorganization [Member] | California [Member]
Commitments And Contingencies [Line Items]
Number of facilities vacated | Facility					1
Fair value of remaining lease obligation					$ 222,000	$ 156,000		$ 222,000
Vacated facility remaining lease term						30 months		33 months

Subsequent Event - Additional I

Subsequent Event - Additional Information (Detail) - Subsequent Event [Member]	Apr. 12, 2018USD ($)$ / sharesshares
Subsequent Event [Line Items]
Preferred shares or subsidiary preferred shares description	As long as the Preferred Shares or Subsidiary Preferred Shares remain outstanding, neither the Company nor the Subsidiary shall take the following actions, without obtaining the prior consent of the holder of the Preferred Shares: (a) effect any alteration, repeal, change or amendment of the rights, privileges or preferences of the Preferred Shares or the Subsidiary Preferred Shares in a manner that adversely affects the rights, privileges or preferences of those shares or any series thereof; (b) amend, modify or repeal any provision of the organizational documents in a manner that adversely affects the powers, preferences or rights of the Preferred Shares or Subsidiary Preferred Shares; (c) agree to any debt financing in an amount in excess of $8,000,000 (such amount being the maximum amount payable by the company under the debt instruments); (d) execute a guarantee; (e) effect any restructuring or liquidation; (f) settle any lawsuit or civil investigation requiring the payment of more than $1,000,000; or (g) execute any document or enter into any arrangement that has a potential liability to the Company in excess of $1,000,000.
Debt financing threshold	$ 8,000,000
Legal settlement threshold	1,000,000
Potential liability under arrangment threshold	$ 1,000,000
First 18 Months [Member]
Subsequent Event [Line Items]
Preferred shares dividend rate	10.00%
19 through 24 Months [Member]
Subsequent Event [Line Items]
Preferred shares dividend rate	20.00%
Month 25 and Thereafter [Member]
Subsequent Event [Line Items]
Preferred shares dividend rate	30.00%
Richard Ressler [Member]
Subsequent Event [Line Items]
Ordinary shares called by warrants | shares	1,953,125
Exercise price | $ / shares	$ 2.56
Warrant exercisable period	5 years
Richard Ressler [Member] | Preferred Shares [Member] | Private Placement [Member]
Subsequent Event [Line Items]
Preferred shares aggregate purchase price	$ 5,000,000
Richard Ressler [Member] | Preferred Shares [Member] | Private Placement [Member] | Presbia PLC [Member]
Subsequent Event [Line Items]
Preferred shares issued | shares	100
Richard Ressler [Member] | Preferred Shares [Member] | Private Placement [Member] | Presbia USA, Inc [Member]
Subsequent Event [Line Items]
Preferred shares issued | shares	4,900